Tremeau is focused on developing non-opioid pain therapies for people with significant unmet need. Our lead clinical stage product, TRM-201 (rofecoxib), is a COX-2 selective NSAID and a potent non-opioid analgesic. We are currently enrolling patients in a Phase III trial of TRM-201 for the treatment of Hemophilic Arthropathy.